Substance P (SP) is involved in neurogenic inflammation and in the pathogenesis of several inflammatory diseases, demonstrating that there is a narrow interrelationship between the nervous system and immunity. Macrophage functions are altered in stress, therefore, since SP is a macrophage activator, its biological effect has been intimately linked to stress. In fact, SP enhances LPS-induced macrophage TNFa production from stressed animals and stimulates the production of IL-8 CXC chemokine response in a mast cell line in vitro. The stress-induced cytokines from macrophage also alter and contribute to inflammation. Understanding the pathophysiology of inflammation and the role ofthe chemical mediator SP may improve inflammation management.
Immune inflammation is a part of innate and adaptive immune response to microbes, antigens and cytokines (1-6). The migration of activated T lymphocytes to sites of inflammation is part of a general process of leukocyte recruitment (7) (8) (9) (10) (11) . This process is due to the actions of several cytokines (12) (13) (14) (15) (16) (17) . Substance P (SP) was first discovered in 1931 and isolated by Leeman S. et al. in the 70's and was shown to be an undecapeptide (18) (19) . There is a good deal of evidence to support the hypothesis that SP is one ofthe most important neurotransmitters and neuromodulators present in the human brain (20) (21) (22) . Its biological effect has been intimately linked to the pathophysiology of several relevant neurological and psychiatric disorders, such as migraine, asthma, nausea, inflammatory bowel syndrome, anxiety, depression and stress (23) (24) (25) . For decades, research has demonstrated that chronic diseases characterized by dysregulation of inflammation are particularly susceptible to exacerbation by stress and emotion (23) . Likewise, rates of depression and anxiety are overrepresented in individuals suffering from chronic inflammatory diseases. In recent years, substance P has been implicated in both pathophysiology of inflammatory disease and the pathophysiology of depression, anxiety and stress (23) .
Perceived stress has long been allied with disturbances of the dynamic equilibrium established between the nervous, endocrine and immune systems, thus triggering or aggravating disease manifestation. For example, several common skin diseases are now acknowledged to be worsened by psychological stress, particularly immunodermatoses such as atopic dermatitis, psoriasis, seborrheic eczema, prurigo nodularis, lichen planus, chronic urticaria, alopecia areata and pruritus sine materia (26) . Pruritus is perhaps the most common symptom associated with the majority of these inflammatory skin diseases, and acute as well as chronic stress perceptions are recognized to trigger or enhance pruritus. A wealth of mediators released systemically or locally in the skin in response to stress increase sensory innervation, upregulate the production of other pruritogenic agents, perpetuate (neurogenic) inflammation and lower the itch threshold (27) . This demonstrates that pathogenesis of atopic dermatitis involves the interactions of immune and neuroendocrine systems with SP participation.
Stress primarily exacerbates allergic dermatitis via SP-dependent cutaneous neurogenic inflammation and subsequent local cytokine shifting and should be considered as a therapeutic target. Recently, high levels of neurotrophic factors have been found in bronchial asthma. These factors include nerve growth factor, brain-derived neurotrophic factor, and leukemia inhibitory factor (28) . Neurotrophic factors are first synthesized in bronchial epithelial cells, immune cells, and other cells in the airway; they are then taken up by the synapse and are finally transported to dorsal root ganglia (C7-T5). Increased neurotrophic factors in dorsal root ganglia promote the synthesis and release of SP. As a result, SP causes a series of reactions such as contraction of airway smooth muscles, secretion of mucous fluids, seepage of capillary vessels, release of mediators of inflammation, and aggravation of airway hyperreactivity, including macrophage activation and subsequent release of cytokines and chemokines (29) (30) . It is interesting to note that the anatomic locations of dorsal root ganglia (C7-T5) are similar to a series of acupuncture points in traditional Chinese medicine. It is hypothesized that dorsal root ganglia may be the targets of acupuncture in the treatment of asthma; in this process, acupuncture has an inhibitory effect on the uptake of neurotrophic factors, or it inhibits the synthesis and release of SP in dorsal root ganglia. As a result, airway neurogenic inflammation in asthma is relieved.
One of the most important capacities of every normal individual's immune system is its ability to recognize, respond and eliminate antigens (with cytokine production), a process that is not harmful for the individual (self), unless cytokine levels are out of the physiological range (31) (32) (33) . Tolerance is an immunological unresponsiveness, and intolerance to self antigens is maintained by several mechanisms (34) (35) (36) . Potentially, neuropeptides serve as the initial insult, resulting in loss of tolerance and autoimmune disease. A fascinating question regarding the pathogenesis of alopecia areata is the potential linkage with the brain. Potentially, neuropeptides serve as the initial insult resulting in loss of tolerance and autoimmune disease. Siebenharr et al. have demonstrated that SP fibers are increased in early lesions, and that SP treatment induces catagen follicles along with activated CD8+ T cells (37) (38) (39) .
Sleep difficulty is one of the hallmarks of menopause. Following recent studies showing no cardiac benefit and increased breast cancer, the question of indications for hormonal therapy has become even more pertinent. Three sets of sleep disorders are associated with menopause: insomnia/depression, sleep disordered breathing and fibromyalgia (40) . The primary predictor of disturbed sleep architecture is the presence of vasomotor symptoms. This subset of women has lower sleep efficiency and more sleep complaints. The same group is at higher risk of insomnia and depression. The "domino theory" of sleep disruption leading to insomnia followed by depression has the most scientific support. High SP and low serotonin have significant potential to affect sleep and mood. Treatment of sleep itself seems to improve; if not resolve fibromyalgia. Menopausal sleep disruption can exacerbate other pre-existing sleep and circadian disorders.
SP is a neuropeptide that is a neurotransmitter and a neuromodulator in the central and peripheral nervous system. There is a link between the immune system and neurogenic inflammation and this is surely influenced by SP (41) . During the past 30 years SP has been identified as an important mediator in the development and progress of inflammation by binding to its high-affinity neurokinin-l receptor (NK-l R). SP is known to have regulatory effects on nervous or non-nervous cells, including immune cells. Neurogenic inflammation encompasses a series of vascular and non-vascular inflammatory responses, triggered by the activation of primary sensory neurons and the subsequent release of inflammatory neuropeptides, including SP (42) . Topical application of exogenous SP enhances wound closure kinetics, suggesting that wounds which have insufficient SP levels to promote a neuroinflammatory response do not have a normal wound repair mechanism.
Several data demonstrate lesion grade dependence of below-level pain development and suggest chemokines as potential candidates for integrating inflammation and central neuropathic pain after spinal cord injury. Accumulating evidence on bone physiopathology has indicated that the skeleton contains numerous nerve fibers, and its metabolism is regulated by the nervous system (46) (47) (48) . Until now, more than 10 neuropeptides have been identified in the bone. SP is a neuropeptide released from axons of sensory neurons, belongs to the tachykinin family and plays important roles in many physiological and pathological processes by acting as a neurotransmitter, neuromodulator, or trophic factor. It activates signal transduction cascades by acting on the neurokinin-I receptor (NK( 1)-R). Previous studies have confirmed that the SP-immunoreactive (IR) axons innervate bone and adjacent tissues, and that their density varies depending on the regions and physiological or pathological conditions. Over the past few decades, it has been found that SP takes part in the stimulation of bone resorption, and its receptors have been demonstrated to be located in osteoclasts (49) . Notably, in studies of skeletal ontogeny, SP-IR axons have been shown to appear at an early stage, mostly coinciding with the sequence of long bone mineralization. These findings, together with data obtained from chemically or surgically targeted nerve deletions, strongly suggest that SP is a potent regulator of skeletal physiology. The specific distribution of SP-IR nerve fibers, the different amount ofSP within regions, and the various levels of expression ofNK(l)-R in targeted cells presumably are related to and participate in .bone metabolism. It can be predicted that the indirect roles of SP through other cytokines are as important as its direct roles in bone metabolism. This new regulating pathway of bone metabolism would have enormous implications in skeletal physiology, and the relevant research might present curative potentials to a spectrum of bone diseases.
Recent studies suggest that neuropeptides, and specifically SP, may be involved in the injury processes, as mentioned before, that occur following acute insults to the brain such as stroke and trauma, and may be responsible, in part, for edema formation (40, (42) (43) (44) (45) . Levels of SP are increased following CNS injury, which is indicative of neurogenic inflammation, and this is associated with injury to the blood-brain barrier, the development of cerebral edema, cell death and functional deficits. Subsequent studies inhibiting neuropeptide release have consistently shown decreased cerebral edema and improved neurological outcome, while SP antagonists administered after the insult are efficacious in reducing post-stroke cerebral edema and neurological deficits. The current review summarizes the evidence supporting the benefits of inhibiting neurogenic inflammation to treat CNS injury. Recent evidence has suggested that neuropeptides, and in particular SP, may play a critical role in the development of morphological injury and functional deficits following acute insults to the brain with consequent cyclooxygenase augmentation and cellular damage (50) (51) (52) (53) (54) . Few studies, however, have examined the role of SP, and more generally, neurogenic inflammation, in the pathophysiology of traumatic brain injury and stroke.
Those studies that have been reported suggest that SP is released following injury to the CNS and facilitates the increased permeability of the blood brain barrier, the development of vasogenic edema and the subsequent cell death and functional deficits that are associated with these events. Inhibition ofthe SP activity, either through inhibition of neuropeptide release, or the use of SP receptor antagonists, have consistently resulted in profound decreases in edema formation and marked improvements in functional outcome (55) .
The isolation of SP and the later discovery of its preferred neurokinin (NK) 1 receptor, led to an intense research effort aimed at elucidating the biological role of SP, particularly within the central nervous system. This wide therapeutic potential triggered an unprecedented research effort, both pre-clinically and clinically, to identify appropriate NKI receptor antagonists and transform them into effective drugs (56) . Aprepitant, a selective highaffinity antagonist of human substance PIneurokinin 1 (NK 1) receptors, is the active ingredient of EMEND which has recently been approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant undergoes extensive metabolism, primarily via CYP3A4 mediated oxidation. It is interesting that this drug is not renal excreted.
